Pharmacology, Toxicology and Pharmaceutical Science
Micelle
100%
Neoplasm
66%
Nanoparticle
41%
Liposome
39%
Macrogol
32%
Malignant Neoplasm
31%
Photodynamic Therapy
29%
Paclitaxel
25%
Photosensitizer
24%
Multiple Myeloma
23%
Tumor Growth
22%
Drug Release
21%
Pharmacokinetics
21%
Dexamethasone
20%
Polycaprolactone
20%
Solid Lipid Nanoparticle
19%
Nanobody
18%
Carbon Tetrachloride
17%
Macrogol Derivative
17%
Curcumin
16%
Nanomedicine
15%
Myeloma
14%
Albumin
14%
Mouse Model
14%
Epidermal Growth Factor Receptor
13%
Polyethylene Glycol
13%
Hematologic Malignancy
13%
Doxorubicin
11%
Bortezomib
11%
Phosphatidylserine
11%
Diseases
10%
Messenger RNA
10%
Drug Conjugate
9%
Kidney Polycystic Disease
9%
Dactolisib
9%
Mitogen Activated Protein Kinase
9%
Chronic Lymphatic Leukemia
9%
Levodopa
9%
Hybrid Mouse Strain
9%
Cytotoxic Factor
9%
Folic Acid
9%
Liposomal Drug Delivery
9%
Breast Carcinoma
9%
Cremophor
9%
Serine Proteinase Inhibitor
9%
Prednisolone
9%
Matrix Metalloproteinase
9%
Pancreas Adenocarcinoma
9%
Carfilzomib
9%
Polyphosphate
9%
Keyphrases
Polymeric Micelles
52%
Lipid Nanoparticles
41%
Photodynamic Therapy
29%
P-hydroxyphenyl
29%
Chlorin
29%
TETRA
29%
Polyethylene Glycol
28%
Nanoparticles
26%
Liposomes
25%
Tumor Growth
25%
Paclitaxel
24%
Endothelial Cells
23%
Bone Marrow
23%
Nanobody
22%
Photosensitizer
22%
Tumor
22%
Multiple Myeloma
22%
Red Blood Cells
20%
Polycaprolactone
20%
Curcumin
19%
Inhibit Tumor
19%
Targeted Liposomes
18%
Nanomedicine
17%
Circulation Time
15%
Cancer Cells
15%
Immune Cells
15%
Tumor Accumulation
15%
Liposomal
15%
Albumin
14%
Liposomal Formulation
14%
Hematological Malignancies
13%
Bortezomib
12%
Doxorubicin
12%
Extracellular Vesicles
12%
Endothelium
12%
Polymeric Nanoparticles
12%
Pharmacokinetics
12%
Platelets
12%
Mouse Model
12%
In Vitro Release
12%
Cell Targeting
11%
Myeloma Cells
11%
Epidermal Growth Factor Receptor
11%
PEGylated Liposomes
11%
Cellular Uptake
11%
Erythrocytes
11%
Biological Media
11%
Angiogenic
11%
Nanoformulation
10%
Flow Condition
10%